文献速递分子诊断质量管理与危急值

院内DPYD基因分型项目用于氟尿嘧啶安全性的实施与早期结果

Implementation and early outcomes of an in-house DPYD genotyping program for fluoropyrimidine safety.
PubMed 文献 · Am J Clin Pathol · 2026-01-01

本研究在多站点癌症中心前瞻性观察2024年5月至2025年7月间院内DPYD基因分型嵌入化疗前流程的实施效果。505例接受氟尿嘧啶类治疗的患者中,439例(86.9%)完成治疗前检测,但仅197例(44.9%)在首周期化疗前获得结果;结论认为院内检测可行,主要实施障碍是结果未能在首次治疗决策前返回。

要点

  • 505例中439例(86.9%)完成治疗前DPYD检测,但仅44.9%在首周期前获结果。
  • 治疗前队列中21例变异杂合子有10例(47.6%)首周期减量,其中9例记录为基因引导。

核心结论

  • 院内DPYD基因分型结合结构化报告在常规实践中可行,可在有临床意义的比例患者中识别可干预变异。
  • 主要实施限制并非检测周转时间本身,而是治疗前开具的检测未能在首次治疗决策前返回结果。

研究设计与样本

  • 前瞻性观察性队列研究,2024年5月至2025年7月在多站点社区-学术癌症中心开展。
  • 617例患者接受院内DPYD基因分型,505例接受全身氟尿嘧啶类治疗者纳入主要分析。
  • 外周血采用TaqMan等位基因辨别法检测c.1905+1G>A、c.1679T>G、c.1236G>A(作为c.1129-5923C>G的替代)、c.2846A>T和c.557A>G。
  • 仪器原始输出经内部自动化流程处理,支持基因型判定、质量控制审核、表型与活性分配,并在医学主任审核后生成报告释放至电子健康记录。

主要发现

  • 505例纳入患者中,439例(86.9%)进行治疗前检测,但仅197/439(44.9%)在首周期化疗前获得结果。
  • 治疗前队列中,21例DPYD变异杂合子有10例(47.6%)在首周期减量,其中9例减量记录为基因引导。
  • 505例中5例(1.0%)发生需紧急评估或住院的严重治疗相关不良事件,包括1例c.1236G>A杂合子其检测结果在治疗开始后返回。

临床怎么用

  • 将DPYD基因分型嵌入化疗前工作流程,并配套自动化判读、表型分配和电子报告,可支持基因引导的剂量决策。
  • 需优化流程以确保治疗前开具的检测结果在首周期化疗决策前返回,而非仅关注检测周转时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fluoropyrimidines are widely used in the treatment of solid tumors but may cause severe toxicity in patients with reduced dihydropyrimidine dehydrogenase activity caused by specific DPYD variants. Although pretreatment DPYD genotyping is guideline supported, implementation remains inconsistent when testing, interpretation, and result reporting are not integrated into routine care pathways. This study evaluated the implementation of an in-house DPYD genotyping program embedded in prechemotherapy workflows at a multisite cancer center. METHODS: A prospective observational cohort study was performed from May 2024 through July 2025 at a multisite community-academic cancer center. Peripheral blood specimens underwent in-house DPYD genotyping for c.1905 + 1G > A, c.1679T > G, c.1236G > A as a proxy for c.1129-5923C > G, c.2846A > T, and c.557A > G using TaqMan allelic discrimination. Raw instrument output was processed through an internally developed automated pipeline that supported genotype calling, quality control review, phenotype and activity assignment, and generation of a note with this information for release into the electronic health record after medical director review. Of 617 genotyped patients, 505 who received systemic fluoropyrimidine-based therapy were included in the primary analysis. RESULTS: Among 505 included patients, pretreatment testing was performed in 439 (86.9%), although only 197 of 439 (44.9%) had results available before cycle 1 chemotherapy. Twenty-two (4.4%) patients were heterozygous for a DPYD variant: c.1236G > A in 11, c.2846A > T in 5, c.1905 + 1G > A in 4, and c.557A > G in 2. In the pretreatment cohort, 10 of 21 (47.6%) patients heterozygous for a DPYD variant underwent dose reduction at cycle 1, and 9 of these reductions were documented as genotype guided. Severe treatment-related adverse events requiring urgent evaluation or hospitalization occurred in 5 of 505 (1.0%) patients, including 1 patient heterozygous for a c.1236G > A variant whose result returned after treatment initiation. CONCLUSIONS: In-house DPYD genotyping with integrated clinical reporting was feasible in routine practice and identified actionable variants in a clinically meaningful proportion of patients. The principal implementation limitation was not assay turnaround time itself but rather failure to return results before the first treatment decision in pretreatment-ordered cases. These findings support the value of laboratory-led pharmacogenomic programs that combine rapid testing, structured interpretation, and direct electronic reporting.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Virk H, Challa S, Sadri N, et al. Implementation and early outcomes of an in-house DPYD genotyping program for fluoropyrimidine safety. Am J Clin Pathol. 2026. PMID: 42803377. doi:10.1093/ajcp/aqag104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。